By Colin Kellaher
CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB.
The Boston clinical-stage company said the Phase 2b study didn't meet statistical significance thresholds for its primary endpoint of change in a measure of the disease or any of its key secondary endpoints.
CervoMed said it is pausing all preparations for a planned Phase 3 study until it completes a full analysis of the Phase 2b study results.
Trading in shares of CervoMed, which closed Monday at $10.25, was halted premarket on Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 10, 2024 07:21 ET (12:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.